8-K: Anteris Secures EU Clearance for DurAVR THV Global Trial

Anteris Technologies Global Corp. announced its first European regulatory clearance from the Danish Medicines Agency to commence the DurAVR Transcatheter Heart Valve global pivotal trial.

Summary

• Anteris Technologies Global Corp. has received regulatory clearance from the Danish Medicines Agency to initiate the DurAVR Transcatheter Heart Valve (THV) global pivotal trial, named the PARADIGM Trial.
• The PARADIGM Trial is a prospective randomized controlled trial (RCT) designed to assess the safety and effectiveness of the DurAVR biomimetic valve compared to commercial TAVR devices.
• Patient recruitment at Danish centers is expected to begin in the fourth quarter of 2025.
• The trial plans to enroll approximately 1000 patients in an All Comers Randomized Cohort, with a 1:1 randomization between DurAVR THV and commercially available TAVRs.
• The primary composite endpoint for the trial includes all-cause mortality, all stroke, and cardiovascular hospitalization at one year post-procedure.
• Anteris plans to expand the trial across the United States, Europe, and Canada, with an Investigational Device Exemption (IDE) application currently under review by the U.S. FDA, with approval expected in the near term.
• Successful completion of the trial is intended to support both Premarket Approval (PMA) in the U.S. and CE Mark approvals in Europe for the DurAVR THV.

Sentiment

Score: 8

Explanation: The filing announces a major positive regulatory milestone (first European clearance for a global pivotal trial) and outlines a clear path towards commercialization for a key product. This significantly de-risks the development pathway and indicates strong progress.

Positives

• Securing the first European regulatory clearance (from the Danish Medicines Agency) is a significant milestone, enabling the launch of the global PARADIGM Trial.
• The PARADIGM Trial is a global, multi-center study designed with world-leading experts, attracting significant interest from clinicians globally.
• The trial's design as a prospective randomized controlled trial (RCT) provides Level 1 evidence, the highest level for determining effectiveness, which is crucial for regulatory approvals.
• Management anticipates strong enthusiasm from investigators will lead to efficient recruitment and timely study advancement.
• The DurAVR THV is a biomimetic valve designed to mimic a healthy human aortic valve and replicate normal aortic blood flow, potentially offering superior hemodynamic performance.
• The DurAVR THV utilizes ADAPT tissue, an FDA-cleared anti-calcification technology with over 10 years of clinical use and distribution in over 55,000 patients worldwide.
• The commencement of this trial marks the beginning of the commercialization planning phase, moving towards global approvals and broader patient access to the technology.

Risks

• Forward-looking statements regarding the planned expansion, results, contours of the PARADIGM Trial, and timing of IDE approval are subject to risks, uncertainties, and assumptions.
• Specific risks are described under 'Risk Factors' in Anteris' Annual Report on Form 10-K for the fiscal period ended December 31, 2024, filed with the SEC and ASX.

Future Outlook

Anteris plans to drive the global PARADIGM Trial through the addition of further countries and sites in the near term, with planned expansion across the United States, Europe, and Canada. FDA approval for the IDE application is expected in the near term. Management believes strong enthusiasm from investigators will translate into efficient recruitment and timely study advancement, leading to meaningful data that could support both PMA and CE Mark approvals. This marks the beginning of the commercialization planning phase as the company moves towards global approvals.

Management Comments

• Chris Meduri, M.D., Chief Medical Officer: "Receiving initial approval in Europe is an important milestone as it signals the launch of the global PARADIGM Trial. This groundbreaking study has been designed with world-leading experts and is attracting significant interest from clinicians globally, reflecting the potential for DurAVR to transform care for patients with aortic stenosis."
• Dr. Michael Reardon and Professor Stephan Windecker, Study Co-Chairs: "The PARADIGM Trial enables us to bring promising new technology to patients across all surgical risk groups, building on the growing body of evidence supporting the DurAVR THVs favorable hemodynamic performance. We look forward to contributing meaningful data which could support both PMA and CE Mark approvals."
• Wayne Paterson, Vice Chairman and CEO: "This is a watershed moment in the company's life cycle and marks the beginning of the commercialization planning phase as we march towards global approvals. Anteris is excited to be able to allow access to an increasing pool of patients globally who will benefit from this life saving technology."

Industry Context

This announcement positions Anteris as a significant innovator in the structural heart market, specifically in the treatment of severe calcific aortic stenosis. The initiation of a global pivotal trial for a biomimetic transcatheter heart valve (THV) directly addresses a large and growing patient population, competing with established transcatheter aortic valve replacement (TAVR) devices. The focus on a biomimetic design and ADAPT tissue technology suggests a differentiated approach aimed at improving long-term patient outcomes and hemodynamic performance compared to existing commercial TAVRs.

Comparison to Industry Standards

• The PARADIGM Trial is a head-to-head study comparing the DurAVR THV against "commercially available and approved THVs," directly benchmarking its performance against current industry standards.
• The trial's design as a prospective randomized controlled trial (RCT) represents Level 1 evidence, which is the highest standard for clinical evidence in medicine, minimizing bias and allowing for clear comparison between treatment groups, a rigorous approach often sought by regulatory bodies and clinicians.
• The DurAVR THV's biomimetic design aims to replicate normal aortic blood flow, potentially offering advantages over conventional TAVR devices in terms of physiological performance.

Stakeholder Impact

• Shareholders: Positive impact due to a significant de-risking event, clear progress towards commercialization, and potential for future revenue generation.
• Patients: Potential for access to a new, potentially superior, life-saving therapy for aortic stenosis.
• Clinicians/Medical Community: Opportunity to participate in a groundbreaking global trial and access innovative technology for treating aortic stenosis.

Next Steps

• Add further countries and sites for the PARADIGM Trial across Europe, the United States, and Canada.
• Obtain FDA approval for the Investigational Device Exemption (IDE) application in the near term.
• Initiate patient recruitment at Danish centers in 4Q 2025.
• Secure Institutional Review Board (IRB) approval for U.S. study sites.
• Progress towards Premarket Approval (PMA) and CE Mark approvals based on trial results.
• Continue commercialization planning in anticipation of global approvals.

Key Dates

Recommendation

The regulatory clearance for a global pivotal trial is a critical de-risking event for Anteris, signaling a clear and accelerated path towards market entry for its DurAVR THV. The trial's robust design (RCT against commercial TAVRs) and the company's expectation of near-term FDA approval, coupled with the proven ADAPT tissue technology, suggest a high probability of success and significant market potential. This milestone significantly enhances the company's valuation prospects and warrants a strong buy recommendation for long-term investors.

Keywords

Anteris Technologies, DurAVR THV, Transcatheter Heart Valve, PARADIGM Trial, Aortic Stenosis, Medical Device, Regulatory Clearance, Clinical Trial, FDA, CE Mark, Structural Heart, Biomimetic Valve, ADAPT Tissue